

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

- (1) RESIGNATION OF NON-EXECUTIVE DIRECTORS AND
MEMBER OF THE AUDIT COMMITTEE;**
**(2) APPOINTMENT OF NON-EXECUTIVE DIRECTORS AND
MEMBER OF THE AUDIT COMMITTEE;**
AND
(3) CHANGE OF AUTHORIZED REPRESENTATIVE

INTRODUCTION

Reference is made to (i) the joint announcement dated December 12, 2022 issued by the Offeror and the Company; (ii) the composite offer and response document dated January 3, 2023 jointly issued by the Offeror and the Company (the “**Composite Document**”); (iii) the joint announcement dated January 26, 2023 issued by the Offeror and the Company; and (iv) the joint announcement dated February 9, 2023 issued by the Offeror and the Company. Unless otherwise stated, capitalized terms used in this joint announcement shall have the same meanings as those used in the Composite Document.

RESIGNATION OF NON-EXECUTIVE DIRECTORS AND MEMBER OF THE AUDIT COMMITTEE

Pursuant to the Irrevocable Undertakings, the board (the “**Board**”) of directors (the “**Director(s)**”) of Acotec Scientific Holdings Limited (the “**Company**”) would like to announce that with effect from February 9, 2023:

- (i) Mr. Chen CHEN (“**Mr. Chen**”) has resigned as a non-executive Director, a member of the audit committee of the Company (the “**Audit Committee**”) and an authorized representative of the Company (the “**Authorized Representative(s)**”) under Rule 3.05 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”); and

(ii) Mr. Ke TANG (“**Mr. Tang**”) has resigned as a non-executive Director.

Each of Mr. Chen and Mr. Tang has confirmed that he has no disagreements with the Board and there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or to the attention of the Stock Exchange.

The Board would like to express its sincere gratitude to Mr. Chen and Mr. Tang for their contributions to the Company during their tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS AND MEMBER OF THE AUDIT COMMITTEE

The Board is pleased to announce that each of Mr. Arthur Crosswell BUTCHER (“**Mr. Butcher**”) and Ms. June CHANG (“**Ms. Chang**”) has been appointed as a non-executive Director of the Company and Ms. Chang has been appointed as a member of the Audit Committee with effect from February 9, 2023. The Audit Committee comprises two independent non-executive Directors, namely Ms. Kin Yee POON and Dr. Yuqi WANG and one non-executive Director, namely Ms. Chang, with effect from February 9, 2023.

The biographical details of Mr. Butcher are as follows:

Mr. Arthur Crosswell BUTCHER, aged 52, obtained a Bachelor of Arts degree in International Relations from the University of Pennsylvania in May 1992 and a Master’s degree in Business Administration from Columbia University in October 2003, and has been the executive vice president and group president of the Medical Surgical business and Asia Pacific region of Boston Scientific Corporation (“**BSC**”), the controlling shareholder of the Company, since May 2022.

Mr. Butcher has over 26 years of experience in the medical device industry. Since joining Boston Scientific in December 1996 as sales representative of the Urology & Women’s Health division until December 1999, Mr. Butcher has held different management roles, including executive vice president and president of the Asia Pacific region from March 2020 to April 2022, senior vice president and president of the Endoscopy division from July 2016 to February 2020, vice president and general manager of the Endoscopy division in Japan from August 2014 to June 2016, vice president of global marketing of the Endoscopy division from April 2011 to August 2014, vice president of new business development and strategic planning of the Urology & Women’s Health division from September 2009 to April 2011, director of marketing and new business development of the Urology & Women’s Health division from March 2008 to September 2009, director of business development and strategic planning of the Urology & Women’s Health division from January 2006 to March 2008, group marketing manager of the Endourology division from April 2003 to December 2005, principal product manager of the Endourology division from April 2002 to April 2003, and regional sales manager of the Urology & Women’s Health division from December 1999 to April 2002.

The biographical details of Ms. Chang are as follows:

Ms. June CHANG, aged 52, obtained of Bachelor of Arts degree from the Business School of the University of Washington in June 1997 and a Master's degree in International Management from the Thunderbird, The American Graduate School of International Management in May 2001, and is currently the president of the Greater China region of BSC since March 2020. Ms. Chang is also a member of the Chartered Institute of Management Accountants.

Ms. Chang has over 25 years of experience in holding financial and commercial leadership roles in the aerospace, automotive, consumer product and device sectors across North America, Asia Pacific region and the Greater China region. Ms. Chang joined BSC in China in October 2013 as the chief financial officer until March 2015. Ms. Chang has held different management roles in BSC, including the chief finance officer of the Greater China region from April 2015 to August 2016, chief financial officer and senior director of strategic planning, DRM & emerging markets of China from September 2016 to March 2018, vice president of finance of the Greater China region and strategic planning/IAS/DRM & emerging markets of China from April 2018 to May 2018, and vice president and managing director of the Greater China region from June 2018 to February 2020. Prior to joining BSC, Ms. Chang was the group controller of foods and beverages of the Greater China region of PepsiCo from June 2012 to October 2013, and the head of financial planning and analysis of the Greater China region of PepsiCo from July 2008 to June 2012. Ms. Chang was also the category finance leader of the Asia, Middle East and Africa regions of Unilever from July 2001 to June 2008. Ms. Chang was a tax associate of Arthur Andersen & Co. from September 1997 to January 2000.

Each of Mr. Butcher and Ms. Chang has entered into an appointment letter with the Company for his/her position as a non-executive Director of the Company commencing from February 9, 2023, which may be terminated by either party furnishing written notice of not less than one month and subject to retirement and re-election at the annual general meeting pursuant to the articles of association of the Company. No remuneration will be paid to Mr. Butcher and Ms. Chang in relation to their appointment and service as a non-executive director of the Company. The Company shall reimburse them for all reasonable out of pocket expenses properly incurred by them in carrying out their duties or in response to any requests by the Company or the board to perform any duty or service in their capacity as director of the Company.

As at the date of this announcement, each of Mr. Butcher and Ms. Chang (i) save as disclosed above in relation to BSC, does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (ii) does not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not hold other positions with the Company and its subsidiaries; and (iv) save as disclosed below, does not hold any interests or short positions in shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong):

Name	Company or associated corporation of the Company	Number of securities/ underlying securities held
Arthur Crosswell Butcher	Boston Scientific Corporation	352,620
June Chang	Boston Scientific Corporation	172,398

Save as disclosed above, as at the date of this announcement, the Board is not aware any other information in relation to Mr. Butcher's and Ms. Chang's appointments that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warm welcome to Mr. Butcher and Ms. Chang upon their joining the Board.

CHANGE OF AUTHORIZED REPRESENTATIVE

The Board announces that Mr. Chen has ceased to act as one of the Authorized Representatives with effect from February 9, 2023, and Ms. Jing LI has been appointed as the one of Authorized Representatives in place of Mr. Chen with effect from February 9, 2023. Please refer to the Company's 2021 annual report for the biographic details of Ms. Jing LI.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, February 9, 2023

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.